INTRODUCTION
Methotrexate (MTX) is an analogue of aminopetrin and the most widely antifolate used in the treatment of certain neoplastic disease, sever psoriasis and adult rheumatoid arthritis 
High-dose methotrexate (HDMTX) chemotherapy with leucovorin (LV)
rescue is administered to prevent extramedullary infiltration and it is very important ALL therapy [5] .
. Unfortunately, MTX therapy may lead to myelosuppression, acute liver toxicity, nephrotoxicity, mucositis, and neurotoxicity [4, [6] [7] [8] [9] [10] [11] .MTX-associated toxicity is associated with several factors including dose, the duration of administration, patient risk factors, and genetic factors [12, 13] . There are no sufficient data involving the use of HDMTX pharmacokinetic and toxicity information to anticipate hematologic toxicity in children with ALL.
Delayed MTX elimination was defined by either MTX concentration >1 μmol/L at 48 h or >0.1 μmol/L at 72h [14, 15] .
. Kidney These chemotherapeutics were administered when ANC is ≥300/μL, and platelet count is ≥50x10 9 /L. HDMTX will be held if total bilirubin 2 mg/dl and direct bilirubin 1.4 mg/dl. However, 6-mercaptopurine may be held in the presence of ANC 300/ μL, platelet count 50000/ μL or grade 3 or 4 mucositis. Dosage of 6-mercaptopurine subsequent courses may be reduced to 25 mg/m 2 /day in patients who have prolonged neutropenia after HDMTX and 6-mercaptopurine treatment. At least two hours before HDMTX, prehydration IV fluid (D 5 W+ 40 mEq NaHco 3 /L) will be administered at the rate of 200 ml/m 2 /hr provided that urinary pH is ≥6.5. Leucovorin [15mg/m 2 IV or PO for standard/high-risk] will be started at 42 hrs after the start of MTX and repeat every 6 hrs. The dosage of leucovorin will be increased in patients with high plasma MTX concentrations (1.0 µM at 42 hrs) and continued until the MTX concentration is less than 0.10 µM.
Complete Blood Counts and MTX Level Assessments
In the course of 102 infusions of HD-MTX, the MTX plasma level was measured at 42 h after HD MTX infusion. Hemoglobin (Hb), absolute neutrophil count (ANC), platelet (PLT) count, red blood count (RBCs) and TLC (total leukocytes count) were determined before MTX administration and on the 5 th and 9 th day following MTX infusion using Automated Hematology Analyzer. MTX concentration at 42 h was measured by high performance liquid chromatography (HPLC) assay.
Evaluation of Myelotoxicity
Hematological toxicity or myelotoxicity signs were determined by absolute neutrophil count and hemoglobin according to Common Terminology Criteria for Adverse Events (CTCAE) [20] (Table 1) .
Statistical Analysis :
Statistical analyses of data were done by Prism 6, Graph pad, CA, USA. Results were expressed as mean ± standard deviation. Statistical differences were sought using Student's t-test or one way analysis of variance (ANOVA) followed by Fisher's least significant difference (LSD) and or post hoc test (if more than two sets of data were being compared). Differences were considered significant at a P<0.05. (Table 2) .
RESULTS

In
Gradual decrease in myelotoxicity after 5 days of MTX administration was shown. However, there is gradual increase in myelotoxicity after 9 days of MTX administration with regard to MTX cycles (Tables 3-4, Figure 1 ).
In addition, Table (5, 6) show that there is no statistical difference in MTX level at 42 h between patients with or without myelotoxicity after 5 and/or 9 days of MTX infusion. Figure ( 2) also illustrates that there is a gradual increase in% MTX delayed elimination with regard to MTX cycles. 
DISCUSSION
Consolidation phase is considered avaluable and important step in the treatment of children with ALL. The use of high dose methotrexate, sometimes in combination with 6-mercaptopurine (6-MP) has significantly contributed to cure children (70-80%). In this study administration of MTX infusion for 5 days induced significant reduction in TLC, ANC, RBCs, Hb levels and PLT count after 5 days of MTX infusion. Similar data was observed during 9 days administration except the effect on PLT count and Hb level. So the myelotoxicity will be decreased. Additionally, dosage of 6-mercaptopurine may be reduced to 25 mg/m 2 /day in patients who have prolonged neutropenia after HDMTX and 6-mercaptopurine treatment [27] and This study explore that there is a gradual increase in MTX delayed elimination with regard to MTX cycles. This may be consistent with the results of Bauters et al. [34] . They reported that high MTX levels (72 h) were frequently observed upon intake of cola beverages. Higher MTX levels were more common after intake of cola during the first and/or second day after the start of HD-MTX infusion. Santucci et al. [35] explained that Cola beverages have a low pH due to their phosphoric acid content and that may explain its effect on MTX elimination.
CONCLUSION
There is gradual decrease in myelotoxicity after 5 days of MTX administration with regard to MTX cycles. However, there is gradual increase in myelotoxicity after 9 days of MTX administration with regard to MTX cycles. There
